1-7 of 7
Margaret Hills
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Martin Filipits, Urania Dafni, Michael Gnant, Varvara Polydoropoulou, Margaret Hills, Astrid Kiermaier, Evandro de Azambuja, Denis Larsimont, Federico Rojo, Giuseppe Viale, Masakazu Toi, Nadia Harbeck, Kathleen I. Prichard, Richard D. Gelber, Phuong Dinh, Dimitrios Zardavas, Brian Leyland-Jones, Martine J. Piccart-Gebhart, Mitch Dowsett
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 3079–3086.
https://doi.org/10.1158/1078-0432.CCR-17-3473
Published: 01 July 2018
View articletitled, Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
Open the PDF for Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study in another window
Includes: Supplementary data
Journal Articles

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

Alexandra Leary, Abigail Evans, Stephen R.D. Johnston, Roger A'Hern, Judith M. Bliss, Rashmita Sahoo, Simone Detre, Benjamin P. Haynes, Margaret Hills, Catherine Harper-Wynne, Nigel Bundred, Gill Coombes, Ian Smith, Mitch Dowsett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2932–2940.
https://doi.org/10.1158/1078-0432.CCR-14-1428
Published: 30 June 2015
View articletitled, Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Open the PDF for Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) in another window
Includes: Supplementary data
Journal Articles

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6159–6168.
https://doi.org/10.1158/1078-0432.CCR-10-1027
Published: 16 December 2010
View articletitled, A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Open the PDF for A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival

Mitch Dowsett, Ian E. Smith, Steve R. Ebbs, J. Michael Dixon, Anthony Skene, Clive Griffith, Irene Boeddinghaus, Janine Salter, Simone Detre, Margaret Hills, Susan Ashley, Stephen Francis, Geraldine Walsh, on behalf of the IMPACT Trialists
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (2): 951s–958s.
https://doi.org/10.1158/1078-0432.951s.11.2
Published: 01 September 2009
View articletitled, Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival
Open the PDF for Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival in another window
Journal Articles

Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer

Mitch Dowsett, Ian E. Smith, Steve R. Ebbs, J. Michael Dixon, Anthony Skene, Clive Griffith, Irene Boeddinghaus, Janine Salter, Simone Detre, Margaret Hills, Susan Ashley, Stephen Francis, Geraldine Walsh, Roger A'Hern
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 1024s–1030s.
https://doi.org/10.1158/1078-0432.CCR-05-2127
Published: 07 February 2006
View articletitled, Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer
Open the PDF for Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer in another window
Journal Articles

Correlation between Cyclooxygenase-2 Expression and Angiogenesis in Human Breast Cancer

Giles Davies, Janine Salter, Margaret Hills, Lesley-Ann Martin, Nigel Sacks, Mitch Dowsett
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2651–2656.
Published: 01 July 2003
View articletitled, Correlation between Cyclooxygenase-2 Expression and Angiogenesis in Human Breast Cancer
Open the PDF for Correlation between Cyclooxygenase-2 Expression and Angiogenesis in Human Breast Cancer in another window
Journal Articles

Antiproliferative Effects of Idoxifene in a Placebo-controlled Trial in Primary Human Breast Cancer

Mitch Dowsett, J. Michael Dixon, Kieran Horgan, Janine Salter, Margaret Hills, Eileen Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2260–2267.
Published: 01 June 2000
View articletitled, Antiproliferative Effects of Idoxifene in a Placebo-controlled Trial in Primary Human Breast Cancer
Open the PDF for Antiproliferative Effects of Idoxifene in a Placebo-controlled Trial in Primary Human Breast Cancer in another window